Abstract
Introduction: Treatment-resistant depression is a relatively common clinical occurrence: between 60-70% of depressive patients fail to achieve total remission to the initial treatment with selective serotonin reuptake inhibitors (SSRI).
Methods: In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. Evaluation of antidepressant efficacy was carried out through the application of the Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Data were analyzed on an intent-to-treat basis, using the last-observation-carried-forward method.
Results: Mean score on the HDRS at baseline was 26.24±7.21, falling to 13.96±8.00 in week 12 (mean decrease of 46.79%; p<0.0001) The percentages of responders (HDRS total score ≥50%) and patients considered as benefiting from complete remission (HDRS score ≤10) at 12 weeks were 50.4% and 34.5%, respectively. By the end of the treatment, a mean decrease in CGI-I score of 1.88 points was obtained (41.14% of reduction; p<0.0001), and 77% of the patients were evaluated as improved (CGI-I score <4). Nervousness was the adverse effect most frequently reported (5.21%), followed by dryness of mouth (4.38%), and insomnia (3.56%).
Conclusion: The results of this study suggest that the combination strategy with reboxetine appears to be a potentially useful tool in cases of SSRI-resistant depression.
References
-
1
Agüera LF, Rojo JE, Ros S, De la Gándara J, De Pedro JM.
Antidepressant combinations: epidemiological considerations.
Acta Psychiatr Scand.
2005;
112
7-10
-
2
Amsterdam JD, García-España F, Rosenzweig M.
Clomipramine augmentation in treatment-resistant depression.
Depress Anxiety.
1997;
5
84-90
-
3
Avenoso A, Facciolà G, Scordo MG, Spina E.
No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Ther Drug Monit.
1999;
21
577-579
-
4
Berman RM, Narasimhan M, Charney DS.
Treatment-Refractory Depression: Definitions and Characteristics.
Depress Anxiety.
1997;
5
154-164
-
5
Blazer DG, Kessler RC, McGonagle KA, Swartz MS.
The prevalence and distribution of major depression in a National Community Sample: The National Comorbidity Survey.
Am J Psychiatry.
1994;
151
979-986
-
6
Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ.
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
J Clin Psychiatry.
1997;
58
137-145
-
7
Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH.
Mirtazapine augmentation in the treatment of refractory depression.
J Clin Psychiatry.
1999;
60
45-49
-
8
Carpenter LL, Yasmin S, Price LH.
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.
Biol Psychiatry.
2002;
51
183-188
-
9
Cuenca E, Alamo C, López-Muñoz F, Coullaut-Jáuregui J.
Perfil farmacodinámico y farmacocinético de un nuevo antidepresivo.
Psiquiatr Biol.
1999;
6
86-90
-
10
De la Gándara J, Ágüera L, Ros S, De Pedro JM.
Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
Acta Psychiatry Scand.
2005;
112
32-35
-
11
De la Gándara J, Rojo JE, Agüera L, De Pedro JM.
Neuropharmacological basis of combining antidepressants.
Acta Psychiatry Scand.
2005;
112
11-13
-
12
Devarajan S, Dursun SM.
Citalopram plus reboxetine in treatment-resistant depression.
Can J Psychiatr.
2000;
45
489-490
-
13
Dodd S, Horgan D, Malhi GS, Berk M.
To combine or not to combine? A literature review of antidepressant combination therapy.
J Affect Disord.
2005;
89
1-11
-
14
Fava M.
Diagnosis and definition of treatment-resistant depression.
Biol Psychiatr.
2003;
53
649-659
-
15
Fava M, Davidson KG.
Definition and epidemiology of treatment-resistant depression.
Psychiatry Clin North Am.
1996;
19
179-200
-
16
Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM.
Lithium and tricyclic augmentation of fluoxetina treatment for resistant major depression: a double-blind, controlled study.
Am J Psychiatry.
1994;
151
1372-1374
-
17
Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF.
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices.
J Clin Psychiatr.
2000;
61
403-408
-
18
Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A. et al .
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Eur J Pharmacol.
1999;
364
123-132
-
19
Hawley CJ, Sivakumaran T, Ochocki M, Bevan J.
Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression. 13th Congress of European College of Neuropsychopharmacology. Munich, Germany, September.
2000;
9-13
-
20
Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M. et al .
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
J Clin Psychiatry.
2002;
63
826-837
-
21
Joffe RT.
Substitution Therapy in Patients with Major Depression.
CNS Drugs.
1999;
11
175-180
-
22
Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB.
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
J Clin Psychiatry.
2002;
63
181-186
-
23
Kent JM.
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Lancet.
2000;
355
911-918
-
24
Lam RW, Hossie H, Solomons K, Yatham LN.
Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression.
J Clin Psychiatry.
2004;
65
337-340
-
25
Lam RW, Wan DDC, Cohen NL, Kennedy SH.
Combining antidepressants for treatment-resistant depression: a review.
J Clin Psychiatry.
2002;
63
685-693
-
26
Lepine JP, Gastpar M, Mendlewicz J, Tylee A.
Depression in the community: The first pan-European study DEPRES (Depression Research in European Society).
Int Clin Psychopharmacol.
1997;
12
19-29
-
27
López-Ibor JJ, Alamo C, López-Muñoz F, Cuenca E, Rubio G, Otero FJ.
Evolution of the management of depression in Spain from the psychiatrist's perspective. A comparative analysis: 1997 vs. 1982.
Eur Psychiatry.
2000;
15
362-369
-
28
Lucca A, Serretti A, Smeraldi E.
Effect of reboxetine augmentation in SRRI resistant patients.
Hum Psychopharmacol Clin Exp.
2000;
15
143-145
-
29
Martín-Águeda B, López-Muñoz F, Rubio G, Guerra JA, Silva A, Álamo C.
Management of depression in primary care: a survey of general practitioners in Spain.
Pharmacopsychiatry.
2005;
27
305-312
-
30
Moret C.
Combination/augmentation strategies for improving the treatment of depression.
Neuropsychiatr Dis Treat.
2005;
1
301-309
-
31
Nelson JC.
Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
Depress Anxiety.
1998;
7
((Suppl 1))
5-6
-
32
Nelson JC, Mazure CM, Bowers MB, Jatlow PI.
A preliminary open study if the combination of fluoxetine and desipramine for rapid treatment of major depression.
Arch Gen Psychiatry.
1991;
48
303-307
-
33
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH.
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
Biol Psychiatry.
2004;
55
296-300
-
34
Nemeroff CB.
Augmentation strategies in patients with refractory depression.
Depression.
1997;
4
169-181
-
35
Nierenberg AA, Amsterdam JD.
Resistant depression: Definition and treatment approaches.
J Clin Psychiatry.
1990;
51
S39-S47
-
36
O'Reardon JP, Brunswick DJ, Amsterdam JD.
Treatment-resistant depression in the age of serotonin: evolving strategies.
Curr Opin Psychiatry.
2000;
13
93-98
-
37
Pilhatsch MK, Burhgardt R, Wandinger KP, Bauer M, Adli M.
Augmentation with atomoxetine in treatment-resistant depression with psychotic features.
Pharmacopsychiatry.
2006;
39
79-80
-
38
Rojo JE, Ros S, Agüera L, De la Gándara J, De Pedro JM.
Combined antidepressant: clinical experience.
Acta Psychiatry Scand.
2005;
112
25-31
-
39
Ros S, Agüera L, De la Gándara J, Rojo JE, De Pedro JM.
Potentiation strategies for treatment-resistant depression.
Acta Psychiatr Scand.
2005;
112
14-24
-
40
Rubio G, San L, López-Muñoz F, Alamo C.
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
J Affect Disord.
2004;
81
67-72
-
41
Rubio G, San L, López-Muñoz F, García-García P, Álamo C.
Tratamiento de combinación con reboxetina en pacientes con depresión mayor no respondedores o con respuesta parcial a inhibidores selectivos de la recaptación de serotonina.
Actas Esp Psiquiatr.
2003;
31
315-324
-
42
Serretti A, Lucca A, Cusin C, Smeraldi E.
Associazione di reboxetine nella depressione resistente a SSRI. .
Giorn Ital Psicopatol.
2001;
7
9-14
-
43
Spier SA.
Use of bupropion with SRIs and venlafaxine.
Depress Anxiety.
1998;
7
73-75
-
44
Stanley B.
An integration of ethical and clinical considerations in the use of placebos.
Psychopharmacol Bull.
1988;
24
180-220
-
45
Tanum L.
Reboxetine: tolerability and safety profile in patients with major depression.
Acta Psychiatr Scand.
2000;
101
((Suppl 402))
37-40
-
46
Tse WS, Bond AJ.
Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship.
Pharmacopsychiatry.
2006;
39
175-179
-
47
Zajecka JM, Jeffriess H, Fawcett J.
The Efficacy of Fluoxetine Combined with a Heterocyclic Antidepressant in Treatment-Resistant Depression: A Retrospective Analysis.
J Clin Psychiatry.
1995;
56
338-343
Correspondence
F. López-Muñoz
Pharmacology Department · University of Alcalá
C/Juan Ignacio Luca de Tena 8
28027 Madrid
Spain
Phone: +34/91/724 82 10
Fax: +34/91/724 82 05
Email: frlopez@juste.net
